Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ling Yan Wong"'
Autor:
Wieslawa H Dragowska, Sherry A Weppler, Jun Chih Wang, Ling Yan Wong, Anita I Kapanen, Jenna S Rawji, Corinna Warburton, Mohammed A Qadir, Elizabeth Donohue, Michel Roberge, Sharon M Gorski, Karen A Gelmon, Marcel B Bally
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e76503 (2013)
Gefitinib (Iressa(®), ZD1839) is a small molecule inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. We report on an early cellular response to gefitinib that involves induction of functional autophagic flux in phenotypically
Externí odkaz:
https://doaj.org/article/8ebd620cddfb45099c4b8064dc11bf52
Autor:
Corinna Warburton, Anita I. Kapanen, Sharon M. Gorski, Wieslawa H. Dragowska, Elizabeth Donohue, Jun Chih Wang, Jenna S. Rawji, Mohammed A. Qadir, Marcel B. Bally, Karen A. Gelmon, Ling Yan Wong, Michel Roberge, Sherry A. Weppler
Publikováno v:
PLoS ONE
PLoS ONE, Vol 8, Iss 10, p e76503 (2013)
PLoS ONE, Vol 8, Iss 10, p e76503 (2013)
Gefitinib (Iressa®, ZD1839) is a small molecule inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. We report on an early cellular response to gefitinib that involves induction of functional autophagic flux in phenotypically di
Autor:
Dana Masin, Sherry A. Weppler, Mohammed A. Qadir, Guido J J Kierkels, Wieslawa H. Dragowska, Karen A. Gelmon, Anita I Kapanen, Jennifer H.E. Baker, Andrew I. Minchinton, Marcel B. Bally, Ling Yan Wong, Yannick Franssen
Publikováno v:
BMC Cancer, Vol 11, Iss 1, p 420 (2011)
BMC Cancer
BMC Cancer
Background HER2-positive breast cancers exhibit high rates of innate and acquired resistance to trastuzumab (TZ), a HER2-directed antibody used as a first line treatment for this disease. TZ resistance may in part be mediated by frequent co-expressio